Nottingham RRU 2nd Highest Recruiters Globally for GSK NUCALA Severe Asthma Trial
Our research team have been working exceedingly hard on the GlaxoSmithKline NUCALA trial of mepolizumab in patients with severe asthma. Nucala is an add-on treatment for adult patients with severe refractory eosinophilic asthma.
Our team have recruited 10 patients so far, second highest globally, and are continuing to work really hard in keeping recruitment going and liaising closely with the severe asthma service at Nottingham City Hospital.
NUCALA Research Team Photo: Janet, Liz, Charlotte, Tina.
(There are many more unable to make the photo shoot)
Well done everyone.